Phase 2 N=23 Study of Topical SOR007 Ointment for Cutaneous Metastases
Cutaneous Metastasis
Primary: Incidence of Treatment Emergent Adverse Events — 4; 3; 5; 10 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=162 Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer
Actinic Keratosis · Warts · Basal Cell Carcinoma
Primary: Number of Accumulated New Skin Lesions at Month 3 — 65; 103 new skin lesions — p=0.0120
Phase 2 N=95 Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy
Metastatic Colorectal Cancer · Skin Rash · Skin Toxicities
Primary: Percentage of Participants With Specific Grade 2 or Higher Skin Toxicities During the 6-week Skin Treatment Period — 29; 62 percentage of participants
Phase 2 N=11 Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer
Recurrent Skin Carcinoma · Skin Squamous Cell Carcinoma
Primary: Response Rate of Pembrolizumab — 72.73 percentage of participants
Phase 2 N=20 Lymph Node Mapping in Finding Metastatic Disease in Patients With Sebaceous Gland Cancer of the Eyelid
Eyelid Sebaceous Gland Carcinoma
Primary: Sentinel Lymph Node Positivity — 2 Participants
Phase 2 N=40 ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin
Skin Cancer
Primary: Number of Participants With Objective Response (Partial Response, Stable Disease and Progressive Disease) — 14; 4; 19 participants
Phase 2 N=30 Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer
Skin Basal Cell Carcinoma
Primary: Overall Response Rate — 69.7 percentage of tumor lesions
Phase 2 N=10 Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases
Breast Cancer · Breast Neoplasms
Primary: Objective Response (Complete Clinical Response+ Partial Response) — 20 percentage of patients
N/A N=90 Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer
Synchronous Metastasized Breast Cancer · Circulating Tumor Cells
Primary: Overall Survival (OS) — 34.6; 56.2 months — p=0.042
Phase 3 N=102 Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma
Basal Cell Carcinoma
Primary: Percentage of Participants With Histologically Confirmed Patient Complete Response (CR) 3 Months After Last Metvix PDT Cycle — 80 percentage of participants
Phase 2 N=8 Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma
Squamous Cell Carcinoma of Skin · Carcinoma, Squamous Cell
Primary: Objective Response Rate (ORR) — 4; 1; 1 Participants
N/A N=54 Enhancing Skin Cancer Early Detection and Treatment in Primary Care
Cutaneous Melanoma
Primary: Change in Clinician Knowledge in Melanoma Risk and Lesion Identification — 72.1; 80.8 score on a scale — p=0.05
Phase 3 N=66 PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Call Carcinoma
Basal Cell Carcinoma
Primary: Percentage of Participants With Histologically Confirmed Complete Response (CR) — 67; 18 percentage of participants — p=<0.001
Phase 2 N=26 Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma
Metastatic Melanoma
Primary: Complete Response — 7; 3 Participants
Phase 2 N=52 SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
Mucosal Lentiginous Melanoma · Acral Lentiginous Malignant Melanoma
Primary: 2-month Progression-free Survival Rate — .52; .52 proportion of patients
N/A N=776 A Retrospective Evaluation of Superficial Radiation Therapy (SRT) and Non-Melanoma Skin Cancer (NMSC)
Non-melanoma Skin Cancer
Primary: Cure Rate — 751 lesions
N/A N=545 Patterns of Care and Outcomes in Patients With Metastatic Bone Tumors (METABONE)
Metastatic Bone Tumor
Primary: Overall Survival (OS) — 21.5; 12.7; 26.6 months
Phase 4 N=8 Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma
Melanoma
Primary: Th1/Th2 Normalized Gene Expression — 1.029; 0.119; 0.074; 0.192 fold change
Phase 2 N=20 Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma
Mucosal Lentiginous Melanoma · Acral Melanoma · Melanoma
Primary: 4-month Progression-Free Survival Rate — 0.27; 0.125 proportion of patients
Phase 2 N=80 Phase 2 Study of Intralesional PV-10 for Metastatic Melanoma
Melanoma
Primary: Objective Response Rate (ORR) of PV-10 Treated Lesions — 51.3 percentage of participants
Phase 2 N=27 Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker
Melanoma
Primary: Association of Baseline C11-AMT PET SUV Max Value With Objective Response — 6; 6; 1; 13 Participants — p=0.08
Phase 3 N=65 Photodynamic Therapy (PDT) With Metvix Cream 160 mg/g Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Cell Carcinoma
Basal Cell Carcinoma
Primary: Number of Participants With Histologically Confirmed Complete Response — 25; 11 Participants
N/A N=2,165 Patterns of Care and Outcomes in METAstatic Soft Tissue SARComa
Sarcoma · Metastases · Chemotherapy
Primary: Correlation Between Time to Next Treatment (TNT) and Overall Survival (OS) Under First-line Treatment — 0.76 correlation coefficient
Phase 2 N=24 SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer
Breastcancer · Breast Neoplasm
Primary: Number of Patients With Treatment Emergent Adverse Events Occurring in Two or More Patients [Safety] — 24; 11; 8; 7 Participants
N/A N=149 SpotCheck: Comparison of Enhanced Telemedicine Versus In-person Evaluation for the Diagnosis of Skin Cancer
Skin Cancer
Primary: Accuracy of Skin Cancer Diagnosis: In-Person Assessment — 93 percentage of skin lesions
Phase 3 N=163 Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
Breast Cancer · Melanoma
Primary: Concordance of Blue Dye and Lymphoseek — 1.0000 Proportion of Lymph Nodes
Phase 2 N=14 Preventative Skin Care for Children Undergoing Targeted CNS Tumor Therapy
Pediatric Cancer · CNS Tumor, Childhood · Skin Inflammation
Primary: Rate of Cutaneous Reaction — 7 Participants
N/A N=89 Infrared Lymphangiography as a Method of Sentinel Node Identification
Melanoma · Sentinel Node
Primary: Equivalence of ICG and Real Time Lymphangiography to technetium99 and Blue Dye in Localizing Sentinel Nodes — 1.87 number of sentinel nodes per patient
Phase 2 N=16 Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer
Skin Basal Cell Carcinoma
Primary: Overall Response Rate (ORR) — 44; 29 Percentage of participants
N/A N=14,381 The Impact of Total Body Skin Examination on Skin Cancer Detection
Melanoma · Basal Cell Carcinoma · Squamous Cell Carcinoma
Primary: Number of Participants With Suspicious Tumors Detected After Inspection of Problem Area and Inspection of the Full Body. — 810; 631 participants — p=<0.01